Malaria vaccine alternative shows strong protection in mice

A vaccine to protect against malaria had long evaded researchers up until GlaxoSmithKline's ($GSK) submission of its vaccine to the European Medicines Agency. But even the drug giant's candidate against the mosquito-borne scourge has shown only modest protection, underscoring the need for better treatments.

Paludisme : les vaccins contenant plusieurs antigènes pourraient donner de meilleurs résultats

La recherche de nouveaux antigènes, ouvrant la voie à un vaccin contre le Plasmodium falciparum, se poursuit. Dans un article paru mercredi dans « Nature Translational Victime », Faith Osier et ses collègues du programme de recherche KEMRI-Wellcome Trust décrivent une expérience réalisée chez des jeunes patients kenyans, dans laquelle ils ont constaté qu’une combinaison d’un grand nombre d’antigènes était plus efficace que seulement un ou deux pour procurer une protection vaccinale.
Des antigènes au peigne fin

Glaxo Files Its Entry in Race for a Malaria Vaccine

An experimental malaria vaccine GlaxoSmithKline GSK.LN +0.95%  PLC filed with regulators Thursday could help fight one of the world's biggest killers—but rival company Sanaria Inc. has a potentially more effective shot in the works.
If Europe's regulators give Glaxo's vaccine—called RTS,S—the green light, it could be in use as soon as 2015, paving the way for a mass vaccination program across sub-Saharan Africa.

Kenya study reveals new malaria vaccine targets

Although GlaxoSmithKline ($GSK) has submitted its malaria vaccine to the European Medicines Agency for approval, the jab hasn't shown as much promise as hoped, underscoring the need for a better understanding of the malaria parasite and how it affects the human immune system.
By studying just that, scientists from the Wellcome Trust Sanger Institute and Kenya Medical Research Institute have revealed new antigens that had not previously been identified as vaccine targets.

GSK submits application for malaria vaccine candidate

Global healthcare company GlaxoSmithKline (GSK) announced on Thursday that it submitted a regulatory application to the European Medicines Agency (EMA) for its malaria vaccine candidate RTS,S.

Malaria vaccine takes first steps towards market

The world’s first vaccine capable of protecting children from malaria has taken a positive step towards becoming available. This week, GlaxoSmithKline plc (GSK) formally sought a special review under article 58, for its RTS,S vaccine from the European Medicine Agency (EMA). This application follows promising phase III clinical results last year, which showed that, when used with other interventions such as bed nets, the vaccine can provided up to 46% protection against malaria, when given to children 5-17 months old.

Download A world free of the intolerable burden of diseases of poverty

Odile Leroy, European Vaccine Initiative joined us last year at the World Vaccine Congress Europe to present on ‘A world free of the intolerable burden of diseases of poverty’
Download this presentation now to find out more about:
  • Malaria Vaccine Technology Roadmap- What has been achieved in 6 years?
  • Partnering with 46 public institutions (10 in Africa) and 19 private companies

Study of new malaria vaccine shows promise

Scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced on Monday improvements to an experimental vaccine designed to spur production of antibodies against the AMA1 malaria parasite protein.
The new candidate delivers AMA1 protein together with part of another parasite protein, RON2.
The AMA1-RON2 complex is used to attach malaria parasites to red blood cells. The vaccine, when injected into mice, prompted an antibody response that protected the mice from lethal forms of the disease.

Scientists reengineering experimental malaria vaccine

An experimental malaria vaccine that showed early promise but ultimately proved unsuccessful in recent clinical trials is being reformulated as scientists hope to one day deliver the jab to patients in endemic countries.

Genome of yellow fever-carrying mosquitoes mapped

Half the genome of the Aedes agypti mosquito, the main carrier of dengue fever and yellow fever, was recently mapped by entomologists from Virginia Tech.
The map allows researchers to compare the organization and evolution of chromosomes between the Aedes mosquito and the Anopheles gambiae mosquito, which is the major carrier of malaria.